Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Celcuity Inc (NQ: CELC )

12.73 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Celcuity Inc

< Previous 1 2 3 4 Next >
Celcuity to Participate in Cowen's 43rd Annual Health Care Conference
Via ACCESSWIRE
Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Prostate Cancer at ASCO GU Cancers Symposium
Via ACCESSWIRE
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Celcuity Closes $100 Million Private Placement
Via ACCESSWIRE
Celcuity Presents Updated Results of Phase 1b Study of Gedatolisib in Patients with Advanced Breast Cancer at the 2022 San Antonio Breast Cancer Symposium
Via ACCESSWIRE
Celcuity Appoints Polly Murphy, D.V.M., Ph.D., to Board of Directors
Via ACCESSWIRE
Celcuity: Q2 Earnings Insights
  Celcuity (NASDAQ:CELC) reported its Q2 earnings results on Thursday, August 11, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Earnings Scheduled For May 16, 2022
Companies Reporting Before The Bell • AcelRx Pharmaceuticals (NASDAQ:ACRX) is estimated to report quarterly loss at $0.06 per share on revenue of $550.00 thousand. 
Via Benzinga
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session
Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Celcuity Announces First Patient Dosed in Phase 3 VIKTORIA-1 Clinical Trial of Gedatolisib for the Treatment of HR+/HER2- Advanced Breast Cancer
Via ACCESSWIRE
Celcuity to Present Additional Data for Gedatolisib at the 2022 San Antonio Breast Cancer Symposium
Via ACCESSWIRE
Celcuity to Participate in the 13th Annual Craig-Hallum Alpha Select Conference
Via ACCESSWIRE
Celcuity Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Via ACCESSWIRE
Celcuity Inc. Schedules Release of Third Quarter 2022 Financial Results and Webcast/Conference Call
Via ACCESSWIRE
Celcuity Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Via ACCESSWIRE
Earnings Outlook For Celcuity
  Celcuity (NASDAQ:CELC) is set to give its latest quarterly earnings report on Thursday, 2022-08-11. Here's what investors need to know before the announcement. Analysts estimate that Celcuity will... 
Via Benzinga
Celcuity Inc. Schedules Release of Second Quarter 2022 Financial Results and Webcast/Conference Call
Via ACCESSWIRE
Celcuity to Participate in the Canaccord Genuity 42nd Annual Growth Conference
Via ACCESSWIRE
The Daily Biotech Pulse: FDA Tentatively Approves Avadel's Narcolepsy Drug, European Approval Broadens AstraZeneca's Enhertu in Breast Cancer, Pharma Giants' Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Biophytis (NASDAQ:BPTS) stock moved upwards by 15.8% to $0.95 during Monday's after-market session. The company's market cap stands at $15.5 million. 
Via Benzinga
Celcuity Announces FDA Breakthrough Therapy Designation for Gedatolisib for Treatment of HR+/HER2- Metastatic Breast Cancer
MINNEAPOLIS, MN / ACCESSWIRE / July 18, 2022 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for hormonally driven cancers, today... 
From Celcuity Inc.
Via AccessWire
Exposures Product Safety
Celcuity to Participate in Upcoming Craig-Hallum and Jefferies Investor Conferences
MINNEAPOLIS, MN / ACCESSWIRE / May 26, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating... 
From Celcuity Inc.
Via AccessWire
Recap: Celcuity Q1 Earnings
Celcuity (NASDAQ:CELC) reported its Q1 earnings results on Monday, May 16, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Celcuity beat estimated earnings by... 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 123 stocks made new 52-week lows. 
Via Benzinga
Celcuity Inc. Reports First Quarter 2022 Financial Results and Business Updates
- Entered into $100 Million Private Placement Agreement - Finalized pivotal Phase 3 trial design for gedatolisib - Received FDA Fast Track designation for gedatolisib in HR+/HER2- advanced breast... 
From Celcuity Inc.
Via AccessWire
Exposures Product Safety
The Week Ahead In Biotech: Gene & Cell Therapy Conference, Tapering Earnings News, OKYO Pharma IPO And More
Biopharma stocks remained largely unchanged in the week ending May 13, with the defensive nature of the sector coming to its aid. Stocks reacted to the broader market move and earnings news from... 
Via Benzinga
Celcuity Inc. Announces $100 Million Private Placement
Proceeds to Advance Clinical Development of Gedatolisib Including Forthcoming Phase 3 Clinical Study (VIKTORIA-1) MINNEAPOLIS, MN / ACCESSWIRE / May 16, 2022 / Celcuity Inc. (Nasdaq:CELC), a... 
From Celcuity Inc.
Via AccessWire
Earnings Preview For Celcuity
Celcuity (NASDAQ:CELC) is set to give its latest quarterly earnings report on Monday, 2022-05-16. Here's what investors need to know before the announcement. Analysts estimate that Celcuity will report... 
Via Benzinga
Celcuity Inc. Schedules Release of First Quarter 2022 Financial Results and Webcast/Conference Call
MINNEAPOLIS, MN / ACCESSWIRE / May 9, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating... 
From Celcuity Inc.
Via AccessWire
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.